|Classification and external resources|
The porphyrias are a group of rare diseases in which chemical substances called porphyrins accumulate. The body requires porphyrins to produce heme, which carries oxygen in the blood; but, in the porphyrias, there is a deficiency (inherited or acquired) of the enzymes that transform the various porphyrins into others, leading to abnormally high levels of one or more of these substances. This manifests with either neurological complications or skin problems or occasionally both.
Porphyrias are classified in two ways, by symptoms and by pathophysiology. Symptomatically, acute porphyrias primarily cause brain and nerve involvement, often with severe abdominal pain, vomiting, neuropathy and mental disturbances. Cutaneous porphyrias cause with skin manifestations often after exposure to sunlight, as porphyrins react with light. Physiologically, porphyrias are classified as hepatic or erythropoietic based on the sites of accumulation of heme precursors, either in the liver or bone marrow and red blood cells.
The term porphyria is derived from the Greek πορφύρα, porphyra, meaning "purple pigment, a reference to the color of the porphyrins. Although original descriptions are attributed to Hippocrates, the disease was first explained biochemically by Felix Hoppe-Seyler in 1871 and acute porphyrias were described by the Dutch physician Barend Stokvis in 1889.
- 1 Signs and symptoms
- 2 Diagnosis
- 3 Cause
- 4 Pathogenesis
- 5 Management
- 6 Epidemiology
- 7 Culture and history
- 8 Notable cases
- 9 References
- 10 External links
Signs and symptoms
These are acute intermittent porphyria, variegate porphyria, hereditary coproporphyria and ALA dehydrated porphyria. The acute porphyrias primarily affect the nervous system, resulting in episodic crises known as acute attacks. The major symptom of the acute attack is abdominal pain, often accompanied by vomiting, hypertension (elevated blood pressure) and tachycardia. The most severe episodes may develop neurological complications: typically a motor neuropathy (severe dysfunction of the peripheral nerves which innervate muscle), leading to muscle weakness and potentially to quadriplegia (paralysis of all four limbs), as well as central nervous system (brain and spinal cord) symptoms including seizures and coma. Occasionally there may be short-lived, acute psychiatric symptoms such as anxiety, confusion, hallucinations, and very rarely, overt psychosis. All these symptoms resolve once the acute attack passes. Porphyria is not a cause of chronic psychiatric illness, though an association with anxiety and depression has been suggested.
Given the many presentations and the relatively low occurrence of porphyria, the patient may initially be suspected to have other, unrelated conditions. For instance, the polyneuropathy of acute porphyria may be mistaken for Guillain-Barré syndrome, and porphyria testing is commonly recommended in those situations.
These are X-linked protoporphyria (XLPP), congenital erythropoietic porphyria (CEP), porphyria cutanea tarda (PCT)and erythropoietic protoporphyria (EPP). None of these are associated with acute attacks; their primary manifestation is with skin disease. (For this reason, these four porphyrias, along with two of the acute porphyrias which may also show skin manifestations - VP and HCP - are sometimes termed cutaneous porphyrias.)
Skin disease is encountered in those porphyrias where excess porphyria accumulate in the skin. Porphyria are photoactive molecules, and exposure to light results in promotion of electrons to higher energy levels. When these return to the resting energy level or ground state, energy is released. This accounts for the property of fluorescence typical of the porphyrins. Light is absorbed at ultraviolet wavelengths center at 405 nm and reradiated at red wavelengths of approximately 630 nm. In the skin, this causes local damage. Two distinct patterns of skin disease are seen in porphyria:
- Immediate photosensitivity. This is typical of XLPP and EPP. Following a variable period of sun-exposure - typically about 30 minutes, patients complain of severe pain, burning and discomfort in sun-exposed areas. Typically there is nothing to see, though occasionally there may be some redness and swelling of the skin.
- Vesiculo-erosive skin disease. This term refers to the characteristic blistering (vesicles) and open sores (erosions) noted in these patients. It is the pattern of skin disease seen in CEP, PCT, VP and HCP. These changes are noted only in sun-exposed areas such as the backs of the hands and face. Milder skin disease, such as that seen in VP and HCP, consists of increased skin fragility in exposed areas with a tendency to form blisters and erosions particularly after minor knocks or scrapes. These heal slowly, often leaving small scars which may be lighter or darker than normal skin. More severe skin disease is sometimes seen in PCT, with more prominent lessons, darkening of exposed skin such as the face and hypertrichosis: abnormal hair growth on the face, particularly the cheeks. The most severe disease is seen in CEP and a rare variant of PCT known as hepatoerythropoietic porphyria (HEP); here the term photoutilation is used to describe the severe shortening of digits and loss of skin appendages such as hair and nails, and severe scarring of the skin with progressive disappearance of ears, lips and nose. These patients may also show deformed, discolored teeth, gum and eye abnormalities.
Porphyria is diagnosed through biochemical analysis of blood, urine, and stool. In general, urine estimation of porphobilinogen (PBG) is the first step if acute porphyria is suspected. As a result of feedback, the decreased production of heme leads to increased production of precursors, PBG being one of the first substances in the porphyrin synthesis pathway. In nearly all cases of acute porphyria syndromes, urinary PBG is markedly elevated except for the very rare ALA dehydratase deficiency or in patients with symptoms due to hereditary tyrosinemia type I. In cases of mercury- or arsenic poisoning-induced porphyria, other changes in porphyrin profiles appear, most notably elevations of uroporphyrins I & III, coproporphyrins I & III and pre-coproporphyrin.
Repeat testing during an attack and subsequent attacks may be necessary in order to detect a porphyria, as levels may be normal or near-normal between attacks. The urine screening test has been known to fail in the initial stages of a severe life-threatening attack of acute intermittent porphyria.
The bulk (up to 90%) of the genetic carriers of the more common, dominantly inherited acute hepatic porphyrias (acute intermittent porphyria, hereditary coproporphyria, variegate porphyria) have been noted in DNA tests to be latent for classic symptoms and may require DNA or enzyme testing. The exception to this may be latent post-puberty genetic carriers of hereditary coproporphyria.
As most porphyrias are rare conditions, general hospital labs typically do not have the expertise, technology or staff time to perform porphyria testing. In general, testing involves sending samples of blood, stool and urine to a reference laboratory. All samples to detect porphyrins must be handled properly. Samples should be taken during an acute attack, otherwise a false negative result may occur. Samples must be protected from light and either refrigerated or preserved.
Further diagnostic tests of affected organs may be required, such as nerve conduction studies for neuropathy or an ultrasound of the liver. Basic biochemical tests may assist in identifying liver disease, hepatocellular carcinoma, and other organ problems.
The porphyrias are generally considered genetic in nature.
- Sulfonamides, including sulfadiazine, sulfasalazine and trimethoprim/sulfamethoxazole.
- Sulfonylureas like glibenclamide, gliclazide and glimepiride, although glipizide is thought to be safe.
- Barbiturates including thiopental, phenobarbital, primidone, etc.
- Systemic treatment with antifungals including fluconazole, griseofulvin, ketoconazole and voriconazole. Although topical use of these agents is thought to be safe due to minimal systemic absorption.
- Some anaesthetics like ketamine and etomidate.
- Certain Antibiotics like rifapentine, rifampicin, rifabutine, nitrofurantoin and possibly, metronidazole.
- Ergot derivatives including dihydroergotamine, ergometrine, ergotamine, methysergide, etc.
- Certain antiretroviral medications (e.g. indinavir, nevirapine, ritonavir, saquinavir, etc.), progestogens,
- Some anticonvulsants including: carbamazepine, phenytoin and perhaps, valproate.
- Miscellaneous others including: oxycodone, pentazocine, cocaine, gold antirheumatic agents like sodium aurothiomalate, methyldopa, fenfluramine, ethosuximide, flupentixol, flutamide, disulfiram, lidocaine, etc.
Deficiency in the enzymes of the porphyrin pathway leads to insufficient production of heme. Heme function plays a central role in cellular metabolism. This is not the main problem in the porphyrias; most heme synthesis enzymes—even dysfunctional enzymes—have enough residual activity to assist in heme biosynthesis. The principal problem in these deficiencies is the accumulation of porphyrins, the heme precursors, which are toxic to tissue in high concentrations. The chemical properties of these intermediates determine the location of accumulation, whether they induce photosensitivity, and whether the intermediate is excreted (in the urine or feces).
There are eight enzymes in the heme biosynthetic pathway, four of which—the first one and the last three—are in the mitochondria, while the other four are in the cytosol. Defects in any of these can lead to some form of porphyria.
The hepatic porphyrias are characterized by acute neurological attacks (seizures, psychosis, extreme back and abdominal pain and an acute polyneuropathy), while the erythropoietic forms present with skin problems, usually a light-sensitive blistering rash and increased hair growth.
Variegate porphyria (also porphyria variegata or mixed porphyria), which results from a partial deficiency in PROTO oxidase, manifests itself with skin lesions similar to those of porphyria cutanea tarda combined with acute neurologic attacks. All other porphyrias are either skin- or nerve-predominant.
Subtypes of porphyrias depend on which enzyme is deficient.
|Porphyria type||Deficient enzyme||Type of porphyria||Inheritance||Symptoms||Prevalence|
|X-linked protoporphyria (XLPP)||5-aminolevulinate (ALA) synthase (ALAS)||Erythropoietic||X-linked dominant||Photosensitivity, cirrhosis||Rare; about 50 cases reported |
|Aminolevulinate dehydratase deficiency porphyria (ALADP)||5-aminolevulinate dehydratase (ALAD)||Hepatic||Autosomal recessive ||Abdominal pain, neuropathy||Extremely rare; fewer than 10 cases ever reported.|
|Acute intermittent porphyria (AIP)||Hydroxymethylbilane synthase (HMBS) formerly porphobilinogen deaminase (PBGD)||Hepatic||Autosomal dominant ||Periodic abdominal pain, peripheral neuropathy, psychiatric disorders, tachycardia||1 in 10,000–20,000|
|Congenital erythropoietic porphyria (CEP)||uroporphyrinogen synthase (UROS)||Erythropoietic||Autosomal recessive ||Severe photosensitivity with erythema, swelling and blistering. Hemolytic anemia, splenomegaly||1 in 1,000,000 or less.|
|Porphyria cutanea tarda (PCT)||uroporphyrinogen decarboxylase (UROD)||Hepatic||Autosomal dominant ||Photosensitivity with vesicles and bullae||1 in 10,000|
|Hereditary coproporphyria (HCP)||coproporphyrinogen oxidase (CPOX)||Hepatic||Autosomal dominant ||Photosensitivity, neurologic symptoms, colic||1 in 500,000|
|Variegate porphyria (VP)||protoporphyrinogen oxidase (PPOX)||Hepatic||Autosomal dominant||Photosensitivity, neurologic symptoms, developmental delay||1 in 300 in South Africa
1 in 75,000 in Finland
|Erythropoietic protoporphyria (EPP)||Ferrochelatase (FECH)||Erythropoietic||Autosomal dominant ||Photosensitivity with skin lesions. Gallstones, mild liver dysfunction||1 in 75,000–200,000|
Carbohydrates and heme
Often, empirical treatment is required if the diagnostic suspicion of a porphyria is high since acute attacks can be fatal. A high-carbohydrate diet is typically recommended; in severe attacks, a dextrose 10% infusion is commenced, which may aid in recovery.
Hematin (trade name Panhematin) and heme arginate (trade name NormoSang) are the drugs of choice in acute porphyria, in the United States and the United Kingdom, respectively. These drugs need to be given very early in an attack to be effective; effectiveness varies amongst individuals. They are not curative drugs but can shorten attacks and reduce the intensity of an attack. Side effects are rare but can be serious. These heme-like substances theoretically inhibit ALA synthase and hence the accumulation of toxic precursors. In the United Kingdom, supplies of NormoSang are kept at two national centers; emergency supply is available from St Thomas' Hospital, London. In the United States, Lundbeck manufactures and supplies Panhematin for infusion.
Heme Arginate (NormoSang) is used during crises but also in preventive treatment to avoid crises, one treatment every 10 days.
Any sign of low blood sodium (hyponatremia) or weakness should be treated with the addition of hematin or heme arginate or even Tin Mesoporphyrin as these are signs of impending syndrome of inappropriate antidiuretic hormone (SIADH) or peripheral nervous system involvement that may be localized or severe progressing to bulbar paresis and respiratory paralysis.
Cimetidine has also been reported to be effective for acute porphyric crisis and possibly effective for long-term prophylaxis.
Pain is severe, frequently out of proportion to physical signs and often requires the use of opiates to reduce it to tolerable levels. Pain should be treated as early as medically possible, due to its severity. Nausea can be severe; it may respond to phenothiazine drugs but is sometimes intractable. Hot water baths/showers may lessen nausea temporarily, though caution should be used to avoid burns or falls.
It is recommended that patients with a history of acute porphyria, and even genetic carriers, wear an alert bracelet or other identification at all times. This is in case they develop severe symptoms, or in case of accidents where there is a potential for drug exposure, and as a result they are unable to explain their condition to healthcare professionals. Some drugs are absolutely contraindicated for any patients with any porphyria.
Neurologic and psychiatric problems
Patients who experience frequent attacks can develop chronic neuropathic pain in extremities as well as chronic pain in the abdomen. Gut dysmotility, ileus, intussusception, hypoganglionosis, encopresis in children and intestinal pseudo-obstruction have been associated with porphyrias. This is thought to be due to axonal nerve deterioration in affected areas of the nervous system and vagal nerve dysfunction.
Depression often accompanies the disease and is best dealt with by treating the offending symptoms and if needed the judicious use of anti-depressants. Some psychotropic drugs are porphyrinogenic, limiting the therapeutic scope. Other psychiatric symptoms such as anxiety, restlessness, insomnia, depression, mania, hallucinations, delusions, confusion, catatonia, and psychosis may occur.
Seizures often accompany this disease. Most seizure medications exacerbate this condition. Treatment can be problematic: barbiturates especially must be avoided. Some benzodiazepines are safe and, when used in conjunction with newer anti-seizure medications such as gabapentin, offer a possible regime for seizure control. Gabapentin has the additional feature of aiding in the treatment of some kinds of neuropathic pain.
Magnesium sulfate and bromides have also been used in porphyria seizures, however, development of status epilepticus in porphyria may not respond to magnesium alone. The addition of hematin or heme arginate has been used during status epilepticus.
Underlying liver disease
Patients with the acute porphyrias (AIP, HCP, VP) are at increased risk over their life for hepatocellular carcinoma (primary liver cancer) and may require monitoring. Other typical risk factors for liver cancer need not be present.
Hormonal fluctuations that contribute to cyclical attacks in women have been treated with oral contraceptives and luteinizing hormones to shut down menstrual cycles. However, oral contraceptives have also triggered photosensitivity and withdrawal of oral contraceptives has triggered attacks. Androgens and fertility hormones have also triggered attacks.
These are associated with accumulation of porphyrins in erythrocytes and are rare. The rarest is congenital erythropoetic porphyria (C.E.P) otherwise known as Gunther's disease. The signs may present from birth and include severe photosensitivity, brown teeth that fluoresce in ultraviolet light due to deposition of type one porphyrins, and later hypertrichosis. Hemolytic anemia usually develops. Pharmaceutical-grade beta carotene may be used in its treatment. A bone marrow transplant has also been successful in curing CEP in a few cases, although long-term results are not yet available.
The pain, burning, swelling, and itching that occur in erythropoietic porphyrias generally require avoidance of bright sunlight. Most kinds of sunscreen are not effective, but SPF-rated long-sleeve shirts, hats, bandanas, and gloves can help. Chloroquine may be used to increase porphyrin secretion in some EPs. Blood transfusion is occasionally used to suppress innate heme production.
The prevalence of all types of porphyria taken together has been estimated to be approximately 1 in 25,000 in the United States. The worldwide prevalence has been estimated to be somewhere between 1 in 500 to 1 in 50,000 people.
Culture and history
Porphyrias have been detected in all races, multiple ethnic groups on every continent including Africans, Asians, Australian aborigines, Caucasians, Peruvian, Mexican, Native Americans, and Sami. There are high incidence reports of AIP in areas of India and Scandinavia and over 200 genetic variants of AIP, some of which are specific to families, although some strains have proven to be repeated mutations.
The links between porphyrias and mental illness have been noted for decades. In the early 1950s patients with porphyrias (occasionally referred to as "Porphyric Hemophilia") and severe symptoms of depression or catatonia were treated with electroshock.
Vampires and werewolves
In January 1964, L. Illis' 1963 paper, "On Porphyria and the Aetiology of Werwolves", was published in Proceedings of the Royal Society of Medicine. Later, Nancy Garden argued for a connection between porphyria and the vampire belief in her 1973 book, Vampires. In 1985, biochemist David Dolphin's paper for the American Association for the Advancement of Science, "Porphyria, Vampires, and Werewolves: The Aetiology of European Metamorphosis Legends", gained widespread media coverage, thus popularizing the idea.
The theory has been rejected by a few folklorists and researchers as not accurately describing the characteristics of the original werewolf and vampire legends or the disease and for potentially stigmatizing sufferers of porphyria.
The mental illness exhibited by King George III evidenced in the regency crisis of 1788 has inspired several attempts at retrospective diagnosis. The first, written in 1855, thirty-five years after his death, concluded he suffered from acute mania. M. Guttmacher, in 1941, suggested manic-depressive psychosis as a more likely diagnosis. The first suggestion that a physical illness was the cause of King George's mental derangements came in 1966, in a paper "The Insanity of King George III: A Classic Case of Porphyria", with a follow-up in 1968, "Porphyria in the Royal Houses of Stuart, Hanover and Prussia". The papers, by a mother/son psychiatrist team, were written as though the case for porphyria had been proven, but the response demonstrated that many, including those more intimately familiar with actual manifestations of porphyria, were unconvinced. Many psychiatrists disagreed with Hunter's diagnosis, suggesting bipolar disorder as far more probable. The theory is treated in Purple Secret, which documents the ultimately unsuccessful search for genetic evidence of porphyria in the remains of royals suspected to suffer from it. In 2005 it was suggested that arsenic (which is known to be porphyrogenic) given to George III with antimony may have caused his porphyria. Despite the lack of direct evidence, the notion that George III (and other members of the royal family) suffered from porphyria has achieved such popularity that many forget that it is merely a hypothesis. In 2010 an exhaustive analysis of historical records concluded that the porphyria claim was based on spurious and selective interpretation of contemporary medical and historical sources.
The mental illness of George III is the basis of the plot in The Madness of King George, a 1994 British film based upon the 1991 Alan Bennett play, The Madness of George III. The closing credits of the film include the comment that the illness suffered by King George has been attributed to porphyria and that it is hereditary. Among other descendants of George III, theorised by the authors of Purple Secret to have suffered from porphyria (based upon analysis of their extensive and detailed medical correspondence), were his great-great-granddaughter Princess Charlotte of Prussia (Emperor William II's eldest sister) and her daughter Princess Feodora of Saxe-Meiningen. They had more success in being able to uncover reliable evidence that George III's great-great-great-grandson Prince William of Gloucester was reliably diagnosed with variegate porphyria.
It is believed that Mary, Queen of Scots – King George III's great-great-great-great-great-grandmother – also suffered from acute intermittent porphyria, although this is subject to much debate. It is assumed she inherited the disorder, if indeed she had it, from her father, James V of Scotland; both father and daughter endured well-documented attacks that could fall within the constellation of symptoms of porphyria.
Maria I of Portugal, known as "Maria the Pious" or "Maria the Mad" due to both her religious fervour and her acute mental illness that made her incapable of handling state affairs after 1792, is also thought to have suffered from porphyria. Francis Willis, the same physician that treated George III, was even summoned by the Portuguese court, but returned to England after the Portuguese court set him limits as to what treatments he could see through. Contemporary sources, such as the Secretary of State for Foreign Affairs Luís Pinto, noted that the Queen suffered from ever-worsening stomach pains and abdominal spasms — hallmarks of porphyria.
Other commentators have suggested that Vincent van Gogh may have suffered from acute intermittent porphyria. It has also been speculated that King Nebuchadnezzar of Babylon suffered from some form of porphyria (cf. Daniel 4). However, the symptoms of the various porphyrias are so extensive that a wide constellation of symptoms can be attributed to one or more of them.
- Lourenço, Charles Marquez; Lee, Chul; Anderson, Karl E. (2012). "Disorders of Haem Biosynthesis". In Saudubray, Jean-Marie; van den Berghe, Georges; Walter, John H. Inborn Metabolic Diseases: Diagnosis and Treatment (5th ed.). New York: Springer. pp. 521–532. ISBN 978-3-642-15719-6.
- Hoppe-Seyler F (1871). "Das Hämatin". Tubinger Med-Chem Untersuch 4: 523–33.
- Nick Lane (2002-12-16). "Born to the purple: the story of porphyria". Scientific American. Retrieved 5 August 2008.
- Stokvis BJ. "Over twee zeldzame kleurstoffen in urine van zieken". Nederl Tijdschr Geneeskd (in Dutch) 2: 409–417. Reprinted in Stokvis BJ (December 1989). "Over twee zeldzame kleurstoffen in urine van zieken". Ned Tijdschr Geneeskd (in Dutch) 133 (51): 2562–70. PMID 2689889.
- Albers JW, Fink JK (2004). "Porphyric neuropathy". Muscle Nerve 30 (4): 410–422. doi:10.1002/mus.20137. PMID 15372536.
- Thadani H, Deacon A, Peters T (2000). "Diagnosis and management of porphyria". BMJ 320 (7250): 1647–1651. doi:10.1136/bmj.320.7250.1647. PMC 1127427. PMID 10856069.
- "Tests for Porphyria diagnosis". American Porphyria Foundation. Retrieved 17 May 2014.
- Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ (2005). "Recommendations for the diagnosis and treatment of the acute porphyrias". Ann. Intern. Med. 142 (6): 439–50. doi:10.7326/0003-4819-142-6-200503150-00010. PMID 15767622.
- Berkó G, Durkó I (Dec 19, 1971). "[Modification of the Mauzerall-Granick method for the determination of urinary aminolevulinic acid].". Orvosi hetilap (in Hungarian) 112 (51): 3085–6. PMID 5136653.
- Woods, J.S. (1995). "Porphyrin metabolism as indicator of metal exposure and toxicity". In Goyer, R.A. & Cherian, M.G. Toxicology of metals, biochemical aspects 115. Berlin: Springer. pp. 19–52, Chapter 2.
- Tishler, PV. "About Porphyria: Safety database". Porphyria Drug Safety Database. American Porphyria Foundation. Retrieved 26 March 2014.
- Brun, A. "napos". The Drug Database for Acute Porphyria. European Porphyria Network. Retrieved 26 March 2014.
- Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. p. 663. ISBN 978-0-85711-084-8.
- grh.nlm.nih.gov/condition/x-linked sideroblastic anemia
- Table 18-1 in: Marks, Dawn B.; Swanson, Todd; Sandra I Kim; Marc Glucksman (2007). Biochemistry and molecular biology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 0-7817-8624-X.
- Overview of the Porphyrias at The Porphyrias Consortium (a part of NIH Rare Diseases Clinical Research Network (RDCRN)) Retrieved June 2011
- Medscape - Diseases of Tetrapyrrole Metabolism - Refsum Disease and the Hepatic Porphyrias Author: Norman C Reynolds. Chief Editor: Stephen A Berman. Updated: Mar 23, 2009
- Arceci, Robert.; Hann, Ian M.; Smith, Owen P. (2006). Pediatric hematolog. Malden, Mass.: Blackwell Pub. ISBN 978-1-4051-3400-2.
- Singal, AK; Anderson, KE; Pagon, RA; Adam, MP; Ardinger, HH; Wallace, SE; Amemiya, A; Bean, LJH; Bird, TD; Dolan, CR; Fong, CT; Smith, RJH; Stephens, K (2013). "Variegate Porphyria". GeneReviews (Seattle, USA: University of Washington). PMID 23409300. Retrieved 18 April 2015.
- Mustajoki P (1980). "Variegate porphyria. Twelve years' experience in Finland". The Quarterly journal of medicine 49 (194): 191–203. PMID 7433635.
- British Medical Association, Royal Pharmaceutical Society of Great Britain (March 2009). "9.8.2: Acute porphyrias". British National Formulary (BNF 57). United Kingdom: BMJ Group and RPS Publishing. p. 549. ISBN 978-0-85369-845-6.
- American Porphyria Foundation (2010). "Panhematin for Acute Porphyria". Retrieved 5 August 2010.
- Cherem JH, Malagon J, Nellen H (2005). "Cimetidine and acute intermittent porphyria". Ann. Intern. Med. 143 (9): 694–5. doi:10.7326/0003-4819-143-9-200511010-00023. PMID 16263899.
- Birgisdottir BT, Asgeirsson H, Arnardottir S, Jonsson JJ, Vidarsson B (2010). "[Acute abdominal pain caused by acute intermittent porphyria - case report and review of the literature]". Laeknabladid (in Icelandic) 96 (6): 413–18. PMID 20519771.
- Tsao YC, Niu DM, Chen JT, Lin CY, Lin YY, Liao KK (2010). "Gabapentin reduces neurovisceral pain of porphyria". Acta Neurol Taiwan 19 (2): 112–5. PMID 20714961.
- Murray ED, Buttner N, Price BH. (2012) Depression and Psychosis in Neurological Practice. In: Neurology in Clinical Practice, 6th Edition. Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds.) Butterworth Heinemann. April 12, 2012. ISBN 978-1437704341
- Martin A Crook.2006. Clinical chemistry and Metabolic Medicine. seventh edition. Hodder Arnold. ISBN 0-340-90616-2
- Faraci M, Morreale G, Boeri E, Lanino E, Dallorso S, Dini G, Scuderi F, Cohen A, Cappelli B (2008). "Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria". Pediatr Transplant 12 (1): 117–120. doi:10.1111/j.1399-3046.2007.00842.x. PMID 18186900.
- eMedicine > Porphyria, Cutaneous Authors: Vikramjit S Kanwar, Thomas G DeLoughery, Richard E Frye and Darius J Adams. Updated: July 27, 2010.
- Genetics Home Reference > Porphyria Reviewed July 2009
- Denver, Joness. "An Encyclopaedia of Obscure Medicine". Published by University Books, Inc., 1959.
- American Vampires: Fans, Victims, Practitioners, Norine Dresser, W. W. Norton & Company, 1989.
- "Did vampires suffer from the disease porphyria — or not?" The Straight Dope, May 7, 1999.
- Macalpine I, Hunter R (January 1966). "The "insanity" of King George 3d: a classic case of porphyria". Br Med J 1 (5479): 65–71. doi:10.1136/bmj.1.5479.65. PMC 1843211. PMID 5323262.
- Macalpine I, Hunter R, Rimington C (January 1968). "Porphyria in the royal houses of Stuart, Hanover, and Prussia. A follow-up study of George 3d's illness". Br Med J 1 (5583): 7–18. doi:10.1136/bmj.1.5583.7. PMC 1984936. PMID 4866084.
- Warren, Martin; Rh̲l, John C. G.; Hunt, David C. (1998). Purple secret: genes, "madness" and the Royal houses of Europe. London: Bantam Books. ISBN 0-593-04148-8.
- The authors demonstrated a single point mutation in the PPOX gene, but not one which has been associated with disease.
- Cox TM, Jack N, Lofthouse S, Watling J, Haines J, Warren MJ (2005). "King George III and porphyria: an elemental hypothesis and investigation". The Lancet 366 (9482): 332–335. doi:10.1016/S0140-6736(05)66991-7. PMID 16039338.
- Peters TJ, Wilkinson D (2010). "King George III and porphyria: a clinical re-examination of the historical evidence". History of Psychiatry 21 (81 Pt 1): 3–19. doi:10.1177/0957154X09102616. PMID 21877427.
- Smith, Martin; Smith, Alison (2009-12-21). "Tetrapyrroles: Birth, Life and Death". ISBN 9780387785189. Retrieved 9 April 2014.
- Roberts, Jenifer (2009). The Madness of Queen Maria [The Remarkable Life of Maria I of Portugal]. Templeton Press. ISBN 978-0954558918.
- Loftus LS, Arnold WN (1991). "Vincent van Gogh's illness: acute intermittent porphyria?". BMJ 303 (6817): 1589–1591. doi:10.1136/bmj.303.6817.1589. PMC 1676250. PMID 1773180.
- Beveridge A (2003). "The madness of politics". J R Soc Med 96 (12): 602–604. doi:10.1258/jrsm.96.12.602. PMC 539664. PMID 14645615.
- Cochrane, Archibald L; Blythe, Max (2009) . One Man's Medicine: An Autobiography of Professor Archie Cochrane. Cardiff: Cardiff University. ISBN 978-0-9540884-3-9.
- Allende, Isabel (1995). Paula. New York, NY: HarperCollins. ISBN 0-06-017253-3.
- American Porphyria Foundation
- European Porphyria Initiative
- The British Porphyria Association
- The UK Porphyria Support Community
- The Drug Database for Acute Porphyria - comprehensive database on drug porphyrinogenicity
- Orphanet's disease page on Porphyria